Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Julie Dohm focuses on regulatory matters for pharmaceutical and biotechnology clients. She has handled matters involving a wide-range of important regulatory topics such as preemption, drug promotion, drug shortage, import-export, exclusivity, and generic drug approvals.

Prior to joining the firm, Dr. Dohm served as the lead on compounding for the U.S. Food and Drug Administration (FDA). Between 2016 and 2019, she was responsible for the overall leadership of the agency’s compounding initiative, including inspections and enforcement, policy development, and stakeholder collaboration.

Previous Experience

  • Senior Science Advisor for Compounding, Center for Drug Evaluation and Research, FDA
  • Drugs Counselor, Office of Chief Counsel, FDA
  • Civil Litigator, Office of Chief Counsel, FDA
  • HHS/OGC Outstanding Newcomer Award
  • FDA Commissioner’s Outstanding Service Award